Obesity medications designed to regulate blood sugar could hold secondary capabilities as powerful tools to protect against the effects of growing older. A post hoc exploratory analysis published in Nature Communications reveals the first direct evidence in humans that semaglutide significantly slows down the accumulation of ageing markers in cellular DNA.
The research, conducted by the University of California San Diego, shows that the treatment works by calming chronic inflammation and reducing excess fat around body organs, which helps postpone several molecular signs of decline.
The clinical trial focused on adults with HIV-associated lipohypertrophy, a condition where abnormal fat accumulations build up around the abdomen. Adults living with HIV frequently experience accelerated biological ageing patterns, which persist even when the virus is durably managed through standard antiretroviral therapy (ART).
This specific group provided an ideal clinical model for evaluating candidate treatments, as these biological processes are central in the general population but tend to emerge much earlier.
To evaluate the molecular impact over a 32-week period, the interdisciplinary team analysed paired blood samples collected from 84 participants who completed the study. The researchers tracked cellular ageing by detecting DNA methylation, which are chemical marks on DNA that help regulate how genes are turned on or off without changing the genetic sequence itself.
The group of 45 participants randomised to receive semaglutide exhibited a broad pattern of slower cellular ageing compared to the 39 individuals in the placebo arm. Blood analysis showed that these structural cellular transformations occurred independently of changes in immune cell counts, ensuring that basic shifts in blood composition did not skew the results.
Deceleration across multiple clocks
The international team monitored these cellular transformations across a robust panel of 17 established “epigenetic clocks”. These tracking systems measure biological age equivalents and evaluate health risks by scoring statistical changes across DNA structures. The active treatment group demonstrated remarkable resistance to the standard progression of biological time compared to the placebo group.
The clinical dataset highlighted definitive performance shifts across several highly validated tracking models:
- Ageing pace: Semaglutide slowed the annual pace of biological ageing by nine per cent relative to the placebo group, as measured by the third-generation DunedinPACE clock.
- Mortality risks: The drug significantly reduced underlying biological processes associated with all-cause mortality and age-related chronic disease, as measured by the PCGrimAge clock.
- Epigenetic memory: Active participants showed a substantial reduction on the PhenoAge clock, declining at a rate of 4.9 years per year over the course of the intervention.
“We are not saying that semaglutide reverses ageing or makes people younger,” stated first author Michael Corley, an associate professor at UC San Diego School of Medicine and the Stein Institute for Research on Ageing. “What we are seeing is a signal that it may slow some of the biological processes associated with ageing. With newer GLP-1–based therapies now emerging, the field has an opportunity to test whether different drugs in this class have distinct effects on ageing biology and to identify which patients may benefit most.”
Reversing chronic immune activation
Geroscience investigators isolated distinct biological pathways to explain the broad deceleration observed across multiple organ systems. By potently reducing visceral fat tissue, the medication successfully curbs the toxic inflammatory and metabolic signalling cascades generated by deep abdominal fat. This fat loss reduces chronic immune activation, a destructive pathway that underpins the accelerated decline in vulnerable populations.
“Emerging data also suggest that GLP-1 drugs may reprogram certain cells in different organs, which could help explain why we see effects across multiple aging clocks,” Corley explained. The largest single protective signals emerged inside physiological system clocks tracking inflammation at minus 5.01 years, brain ageing at minus 4.99 years, and metabolic infrastructure at minus 4.72 years. Significant downstream decelerations were similarly observed across heart, kidney, and liver pathways.
The lessons drawn from this high-risk cohort appear directly relevant to the wider population, as the metabolic and inflammatory processes driving HIV-related decline are central to normal human ageing. This link is reinforced by a separate pilot study published in npj Aging, which evaluated semaglutide in individuals with fatty liver disease. That independent 24-week trial confirmed a reduction in mortality risk for 34 per cent of participants, alongside measurable protection of telomere length in nearly 49 per cent of the cohort.
Dashboards and future repurposing
The investigators noted that participants with protected chromosome tips also demonstrated increased walking speeds after treatment, suggesting enhanced physical resilience and better physical function. Larger prospective clinical trials are now required to establish long-term durability, determine optimal dosing windows, and verify whether combining the medication with lifestyle interventions yields greater preventive benefits.
The Stein Institute for Research on Ageing plans to translate these clinical results into individualised “ageing dashboards”. These tracking platforms will leverage blood-based epigenetic clocks to monitor organ-system decline in real time, enabling clinicians to design personalised longevity therapies that target the underlying mechanisms of chronic disease. By utilising approved drug repurposing frameworks, the field can accelerate the translation of metabolic interventions into scalable healthcare tools, say researchers.
